Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Beutler, A.

Search results

  • RSS Feed
(1 - 19 of 19)
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
Kavanaugh, A.; Heijde, D. van der; Beutler, A.; Gladman, D.; Mease, P.; Krueger, G.G.; ... ; Xu, S. 2016
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
Article / Letter to editor
metadata only
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
Kavanaugh, A.; McInnes, I.B.; Mease, P.; Krueger, G.G.; Gladman, D.; Heijde, D. van der; ... ; Beutler, A. 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
Article / Letter to editor
metadata only
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Braun, J.; Baraliakos, X.; Hermann, K.G.A.; Deodhar, A.; Heijde, D. van der; Inman, R.; ... ; Hsu, B. 2014
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Article / Letter to editor
metadata only
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
Kavanaugh, A.; McInnes, I.B.; Mease, P.J.; Krueger, G.G.; Gladman, D.D.; Heijde, D. van der; ... ; Beutler, A. 2013
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
Article / Letter to editor
metadata only
5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study
Kavanaugh, A.; Heijde, D. van der; McInnes, I.B.; Mease, P.; Krueger, G.G.; Gladman, D.; ... ; Beutler, A. 2012
5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study
Article / Letter to editor
metadata only
THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS
Braun, J.; Heijde, D. van der; Hermann, K.G.; Baraliakos, X.; Deodhar, A.; Beutler, A.; ... ; Inman, R. 2012
THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS
Article / Letter to editor
metadata only
Long-term Radiographic Outcome in Psoriatic Arthritis Patients Treated with Golimumab: 104 Week Results from the GO-REVEAL Study
Kavanaugh, A.; Heijde, D. van der; Gladman, D.; Mease, P.; McInnes, L.; Krueger, G.; ... ; Chandran, V. 2012
Long-term Radiographic Outcome in Psoriatic Arthritis Patients Treated with Golimumab: 104 Week Results from the GO-REVEAL Study
Article / Letter to editor
metadata only
Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
Kavanaugh, A.; Heijde, D. van der; McInnes, I.B.; Mease, P.; Krueger, G.G.; Gladman, D.D.; ... ; Beutler, A. 2012
Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
Article / Letter to editor
metadata only
LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB: 104 WEEK RESULTS FROM THE GO-REVEAL STUDY
Kavanaugh, A.; Heijde, D. van der; Chattopadhyay, C.; Gladman, D.; Mease, P.; McInnes, I.; ... ; Beutler, A. 2012
LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB: 104 WEEK RESULTS FROM THE GO-REVEAL STUDY
Article / Letter to editor
metadata only
Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al Reply
Emery, P.; Conaghan, P.G.; Fleischmann, R.; Heijde, D. van der; Keystone, E.C.; Genovese, M.C.; ... ; Rahman, M.U. 2012
Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al Reply
Article / Letter to editor
metadata only
The Effect of Anti-Tumor Necrosis Factor Therapy with Two Different Doses of Golimumab on Radiographic Progression in Definite Ankylosing Spondylitis: 4-Year Results
Braun, J.; Heijde, D. van der; Hermann, K.G.; Baraliakos, X.; Deodhar, A.; Beutler, A.; ... ; GO-RAISE Clinical Investigators 2011
The Effect of Anti-Tumor Necrosis Factor Therapy with Two Different Doses of Golimumab on Radiographic Progression in Definite Ankylosing Spondylitis: 4-Year Results
Article / Letter to editor
metadata only
Sustained Clinical Response with Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of a Randomized, Placebo-Controlled Study
Braun, J.; Heijde, D. van der; Deodhar, A.; Beutler, A.; Mack, M.; Hsu, B.; Inman, R.D. 2011
Sustained Clinical Response with Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of a Randomized, Placebo-Controlled Study
Article / Letter to editor
metadata only
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Emery, P.; Fleischmann, R.; Heijde, D. van der; Keystone, E.C.; Genovese, M.C.; Conaghan, P.G.; ... ; Rahman, M.U. 2011
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Article / Letter to editor
metadata only
Objective. To evaluate the effects of golimumab on radiographic progression in patients with rheumatoid arthritis (RA). Methods. Methotrexate (MTX)-naive patients (in the Golimumab Before Employing... Show moreObjective. To evaluate the effects of golimumab on radiographic progression in patients with rheumatoid arthritis (RA). Methods. Methotrexate (MTX)-naive patients (in the Golimumab Before Employing Methotrexate as the First-Line Option in the Treatment of Rheumatoid Arthritis of Early Onset [GO-BEFORE] study; n = 637) and patients with active RA despite MTX therapy (in the Golimumab in Active Rheumatoid Arthritis Despite Methotrexate Therapy [GO-FORWARD] study; n = 444) were randomly assigned to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4). Golimumab or placebo was administered subcutaneously every 4 weeks. Radiographs of the hands and feet were taken at baseline, week 28, and week 52 in the GO-BEFORE study and at baseline, week 24 (week 16 for patients who entered early escape), and week 52 in the GO-FORWARD study. Radiographs were scored by 2 independent readers in each study using the van der Heijde modification of the Sharp score. Results. In the GO- BEFORE study, the mean +/- SD changes in the modified Sharp score from baseline to week 52 (control period) were 1.4 +/- 4.6 in group 1, 1.3 +/- 6.2 in group 2 (P = 0.266), 0.7 +/- 5.2 in group 3 (P = 0.015), and 0.1 +/- 1.8 in group 4 (P = 0.025). In the GO-FORWARD study, changes from baseline to week 24 (control period) were 0.6 +/- 2.4 in group 1, 0.3 +/- 1.6 in group 2 (P = 0.361), 0.6 +/- 2.7 in group 3 (P = 0.953), and 0.2 +/- 1.3 in group 4 (P = 0.293). Conclusion. Golimumab in combination with MTX inhibited radiographic progression significantly better than did MTX alone in the GO-BEFORE study. Radiographic progression in the GO-FORWARD study was minimal in all treatment arms, precluding an adequate assessment of the effect of golimumab on radiographic progression in this study. Show less
GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY
Kavanaugh, A.; Heijde, D. van der; Chattopadhyay, C.; Gladman, D.; Mease, P.; McInnes, I.; ... ; GO-REVEAL Investigators 2011
GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY
Article / Letter to editor
metadata only
GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES
Emery, P.; Fleischmann, R.; Heijde, D. van der; Keystone, E.; Genovese, M.C.; Conaghan, P.G.; ... ; GO-FORWARD 2011
GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES
Other
metadata only
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; ... ; GO-RAISE Investigators 2010
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
Other
metadata only
GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY
Kavanaugh, A.; Gladman, D.; Heijde, D. van der; Mease, P.; McInnes, L.; Krueger, G.G.; ... ; GO-REVEAL Investigators 2010
GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY
Other
metadata only
Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study
Gladman, D.; Kavanaugh, A.; Heijde, D. van der; Mease, P.; McInnes, I.; Krueger, G.; ... ; Beutler, A. 2010
Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study
Other
metadata only
Golimumab, a New, Human, TNF-alpha Antibody Administered Subcutaneously Every 4 Weeks, in Ankylosing Spondylitis: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study
Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; ... ; Inman, R. 2010
Golimumab, a New, Human, TNF-alpha Antibody Administered Subcutaneously Every 4 Weeks, in Ankylosing Spondylitis: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study
Other
metadata only